# The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.

Study · id `cardio:ct-nct04634500` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04634500](<https://clinicaltrials.gov/study/NCT04634500>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04634500

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

## Technical summary

Registry record NCT04634500. Randomized; double masking; primary purpose treatment. Start 2020-11-18 (actual); primary completion 2021-11-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (enrolled count; ClinicalTrials.gov record NCT04634500, source copy `cardio:ctgov-nct04634500-2022-10-25`, retrieved 2026-10-26)
- Started: 2020-11-18 (actual) (ClinicalTrials.gov record NCT04634500, source copy `cardio:ctgov-nct04634500-2022-10-25`, retrieved 2026-10-26)
- Primary completion: 2021-11-03 (actual) (ClinicalTrials.gov record NCT04634500, source copy `cardio:ctgov-nct04634500-2022-10-25`, retrieved 2026-10-26)
- Completion: 2021-11-03 (actual) (ClinicalTrials.gov record NCT04634500, source copy `cardio:ctgov-nct04634500-2022-10-25`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04634500, source copy `cardio:ctgov-nct04634500-2022-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04634500-2022-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.
- Acronym: ENHANCE-M
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial (`cardio:pubmed-36756676`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: be59cb315e2d4a5987b472f4ad5248290f60d487c1a07a8fb76864f24ca8f056
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
